Intracellular PD Modelling (PD(i)) for the Prediction of Clinical Activity of Increased Rifampicin Dosing

Increasing rifampicin (RIF) dosages could significantly reduce tuberculosis (TB) treatment durations. Understanding the pharmacokinetic-pharmacodynamics (PK–PD) of increasing RIF dosages could inform clinical regimen selection. We used intracellular PD modelling (PD(i)) to predict clinical outcomes,...

Descripción completa

Detalles Bibliográficos
Autores principales: Aljayyoussi, Ghaith, Donnellan, Samantha, Ward, Stephen A., Biagini, Giancarlo A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630509/
https://www.ncbi.nlm.nih.gov/pubmed/31200534
http://dx.doi.org/10.3390/pharmaceutics11060278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630509/
https://www.ncbi.nlm.nih.gov/pubmed/31200534
http://dx.doi.org/10.3390/pharmaceutics11060278

Ejemplares similares